The Ophthalmology Times Group talked to an optometrist practice about their experience with ocular nutraceuticals
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
FDA agrees to expand Atsena's gene therapy trial for XLRS treatment
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001
Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Long-duration spaceflight tests the limits of telemedicine
In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained
Patients with high genetic risk of AMD should avoid instant coffee, investigators say
Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption